Medexus Pharmaceuticals Stock Target Price
| MDP Stock | 2.74 0.07 2.49% |
As of the 13th of February 2026, Medexus Pharmaceuticals secures the Mean Deviation of 1.64, risk adjusted performance of 0.0254, and Downside Deviation of 2.09. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medexus Pharmaceuticals, as well as the relationship between them.
Medexus Pharmaceuticals Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.7643 | Revenue |
Medexus | Target Price |
Medexus Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Medexus Pharmaceuticals from analyzing Medexus Pharmaceuticals' financial statements. These drivers represent accounts that assess Medexus Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Medexus Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 61.1M | 32.0M | 35.9M | 62.5M | 71.9M | 102.7M | |
| Enterprise Value | 103.4M | 109.0M | 80.6M | 75.7M | 87.0M | 127.0M |
Medexus Fundamentals
| Return On Equity | 0.009 | ||||
| Return On Asset | 0.0254 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 107.92 M | ||||
| Shares Outstanding | 32.42 M | ||||
| Shares Owned By Insiders | 7.21 % | ||||
| Shares Owned By Institutions | 3.35 % | ||||
| Number Of Shares Shorted | 102.71 K | ||||
| Price To Book | 1.29 X | ||||
| Price To Sales | 0.88 X | ||||
| Revenue | 108.33 M | ||||
| Gross Profit | 63.95 M | ||||
| EBITDA | 16.81 M | ||||
| Net Income | 2.25 M | ||||
| Cash And Equivalents | 23.97 M | ||||
| Total Debt | 37.18 M | ||||
| Book Value Per Share | 2.19 X | ||||
| Cash Flow From Operations | 24.03 M | ||||
| Short Ratio | 2.48 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 6.89 | ||||
| Number Of Employees | 91 | ||||
| Beta | 1.98 | ||||
| Market Capitalization | 91.1 M | ||||
| Total Asset | 171.84 M | ||||
| Retained Earnings | (61.99 M) | ||||
| Working Capital | (16.74 M) | ||||
| Net Asset | 171.84 M |
About Medexus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medexus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medexus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medexus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medexus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medexus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medexus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Medexus Stock
Moving against Medexus Stock
The ability to find closely correlated positions to Medexus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medexus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medexus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medexus Pharmaceuticals to buy it.
The correlation of Medexus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medexus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medexus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medexus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Medexus Stock
Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.